LOGC - LogicBio Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.65
+0.78 (+6.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.87
Open11.43
Bid6.33 x 900
Ask0.00 x 800
Day's Range11.43 - 13.19
52 Week Range6.70 - 20.07
Volume2,549
Avg. Volume27,964
Market Cap284.553M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.87
Earnings DateAug 21, 2019 - Aug 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.25
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    LogicBio to Present at the Jefferies 2019 Healthcare Conference

    CAMBRIDGE, Mass., May 30, 2019 -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today.

  • Associated Press2 months ago

    LogicBio Therapeutics: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 34 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates

    CAMBRIDGE, Mass., May 14, 2019 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat.

  • Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
    Zacks2 months ago

    Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

    Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

  • Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?
    Zacks2 months ago

    Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

    Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

  • GlobeNewswire3 months ago

    LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia

    LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LB-001, a recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene for the treatment of methylmalonic acidemia (MMA).

  • GlobeNewswire3 months ago

    LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic

    LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced a significant expansion of its leadership team to continue developing its technology platform in preparation for moving its lead product candidate, LB-001, into the clinic. “We are taking a significant step to advance our programs by building out experienced CMC, technology development, program management and clinical teams as we continue to enhance our core technology and move forward with LB-001,” said LogicBio President and CEO Fred Chereau. The new hires will also expand the Company’s significant strengths in the development, manufacturing and characterization of viral vectors.

  • Associated Press3 months ago

    LogicBio Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 41 cents. For the year, the company reported a loss of $17.6 million, or $3.04 per share. LogicBio Therapeutics shares ...

  • GlobeNewswire3 months ago

    LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

    CAMBRIDGE, Mass., April 01, 2019 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably.

  • LogicBio planning first trial of gene editing treatment for children
    American City Business Journals4 months ago

    LogicBio planning first trial of gene editing treatment for children

    The four-year-old biotech is planning to seek FDA approval for its first clinical trial by the end of the year, executives told the Business Journal this week.

  • GlobeNewswire5 months ago

    LogicBio Therapeutics to Present at Upcoming March Conferences

    CAMBRIDGE, Mass., Feb. 25, 2019 -- LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today.

  • GlobeNewswire5 months ago

    LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development

    LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development. Dr. Huttner brings over 15 years of clinical research and development and translational medicine experience to the LogicBio leadership team, as well as a clinical background in pediatrics and neonatology.

  • GlobeNewswire7 months ago

    LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors

    LogicBio Therapeutics, Inc.  (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its Board of Directors. Both have extensive knowledge of rare disease drug development and bring rich insight in the areas of clinical research, regulatory affairs and corporate governance to the board. “Richard and Michael bring tremendous value and expertise to our board, and we’re delighted to be able to draw on their insights as we move toward the clinic in our first indication, the rare genetic disorder methylmalonic acidemia,” said Frederic Chereau, LogicBio’s President and Chief Executive Officer.

  • GlobeNewswire7 months ago

    LogicBio Reports Third Quarter 2018 Financial Results

    CAMBRIDGE, Mass., Dec. 03, 2018 -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably.

  • GlobeNewswire8 months ago

    LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors

    LogicBio Therapeutics, Inc. (LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the launch of a partnership to develop new viral vectors with Children’s Medical Research Institute (CMRI) of Australia, a world leader in the areas of gene therapy, childhood cancer, embryology and neurological diseases. The newly formed AAV Development Program will focus on developing next-generation synthetic adeno-associated virus (AAV) capsids capable of overcoming many of the current limitations of existing viral vectors.

  • GlobeNewswire8 months ago

    LogicBio to Present at the Jefferies 2018 London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 13, 2018 -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in.

  • Benzinga8 months ago

    The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Earnings and U.S. midterm polls continued to positively influence biotech stocks, with the sector notching gains for the second straight week. These are some of the upcoming week's catalysts that could ...

  • PR Newswire9 months ago

    Arix Bioscience plc - LogicBio Announces Closing of Initial Public Offering

    LONDON , October 24, 2018 /PRNewswire/ -- This Announcement Contains Inside Information Within the Meaning of the EU Market Abuse Regulation No.596/2014 LogicBio IPO has closed Arix retains a stake of ...

  • PR Newswire9 months ago

    Chardan Serves as Lead Manager for LogicBio Therapeutics

    NEW YORK , Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), ...

  • Benzinga9 months ago

    LogicBio's IPO: What You Need To Know

    This technology is designed to precisely integrate corrective genes into a patient’s genome to provide a therapeutic effect, according to the company's S-1 filing. The company’s lead product candidate LB-001 is designed to treat methylmalonic acidemia, when the body cannot break down specific proteins and fats. The next steps in clinical research should be initiated by the end of 2019, according to LogicBio.

  • Benzinga9 months ago

    IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . PhaseBio Pharmaceuticals Inc (PHAS) will issue 5 million shares between $12 and $14 Thursday on the Nasdaq. Based in Pennsylvania, ...